Table 3.
Number of doses IV ribavirin received in 38 individuals and reasons for early discontinuation of IV ribavirin.
| Number of doses | N (%) | Reason for discontinuation |
|---|---|---|
| 23–25 | 26 (76.5%) | Completion of therapy |
| 22 | 1 | Rash |
| 20 | 1 | Pancreatitisa |
| 19 | 2 | Junctional bradycardiaa |
| Death (respiratory failure) | ||
| 18 | 1 | Sinus bradycardiaa |
| 15 | 1 | Deviation (only 4 days drug ordered) |
| 13 | 1 | Hyperamylasemia/pancreatitisa |
| 10 | 1 | Sinus bradycardiaa |
| 3 | 1 | Transferb |
| 2 | 2 | Transferb |
| Deathb,c | ||
| 1 | 1 | Deathb,c |
a
Condition may occur from HFRS and unknown if condition is potentiated by ribavirin.
b
Individuals not included in safety analysis (received < four doses IV ribavirin).
c
Death occurred within 24 h of IV ribavirin initiation in individuals with severe sepsis-like presentation at the time of drug initiation.